Our project builds on dopamine (DA) neuron-specific models of Akt1-deficiency in the mouse brain. Our goal is to determine if converging findings of pathologically altered Akt signaling in different neuropsychiatric disorders including depression and addiction are functionally related. To reveal common features of impaired Akt signaling that may impact on depression-like and addictive behaviors, we will first use the social defeat paradigm to induce depression-like behaviors in Akt1-mutant mice and congenic controls. Stressed mice will then be exposed to the psychostimulant cocaine. By combining depression- and addiction-related behavioral paradigms in Akt1-mutant mice, we will test whether impairment of Akt signaling due to genetic deficits is further enhanced by stress to augment behavioral responsiveness to cocaine. Results from our experiments will identify fundamental molecular mechanisms by which cocaine and other drugs of abuse manipulate brain circuitry, and explain how disease-related genetic variations and acquired impairments in Akt signaling due to stress increase susceptibility to their effects. The functional characterization of this pivotal signaling pathway in DA neurons holds significant potential for the development of biomarkers and approaches for risk assessment and treatment of addiction, depression and other neuropsychiatric disorders, and improves the understanding of common risk factors shared among neuropsychiatric disorders.

Public Health Relevance

Drug addiction is a significant but preventable health concern;however, once the addiction process has been initiated, reversing it is difficult. Understanding the biological substrates of addiction is therefore of critical importance. This project is focused on the Akt kinase intracellular signaling pathway and builds on biochemical and genetic findings of impaired AKT1 signaling in neuropsychiatric disorders with high comorbidity for addiction. To model impaired Akt signaling, we will study genetically-modified models of altered Akt1 signaling in the mouse brain with an emphasis on examining Akt1 deficiency as a possible risk and vulnerability factor in determining behavioral responsiveness to cocaine.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DA032280-01A1
Application #
8323032
Study Section
Special Emphasis Panel (ZDA1-SXC-E (12))
Program Officer
Volman, Susan
Project Start
2012-03-15
Project End
2014-02-28
Budget Start
2012-03-15
Budget End
2013-02-28
Support Year
1
Fiscal Year
2012
Total Cost
$211,250
Indirect Cost
$86,250
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016